Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 408

Sort by

Sort Order Select

Journal Articles

Proteogenomic analysis of NPM1-mutated AML reveals clinical heterogeneity related to differentiation states and mitochondrial metabolism

Sebastian Wolf, Josefine Jakob, Björn Häupl, Annika Meid, Daniela Späth, Felicitas R Thol, Hubert Serve, Konstanze Döhner, Hartmut Döhner, Thomas Oellerich

Blood (2025) 146 (Supplement 1): 660.

https://doi.org/10.1182/blood-2025-660

Published: 2025

Journal Articles

ALIDHE: An ongoing open-label phase 3b study investigating ivosidenib with azacitidine in clinical practice in adult patients with newly diagnosed mutant isocitrate dehydrogenase 1 (mIDH1) Acute Myeloid Leukemia (AML) ineligible for intensive induction chemotherapy (IC)

Blood (2025) 146 (Supplement 1): 3443.

https://doi.org/10.1182/blood-2025-3443

Published: 2025

Journal Articles

CYP3A4 inhibitors (CYP3A4i) and myelosuppression in patients (Pts) with newly diagnosed mutant isocitrate dehydrogenase 1 (mIDH1) Acute Myeloid Leukemia (AML) in the phase 3 AGILE study

Andre Schuh, Pau Montesinos, Christian Recher, Michael Heuser, Susana Vives, Ewa Zarzycka, Marta Riva, Rodrigo Calado, Su-Peng Yeh, Courtney DiNardo, Mohammad Hossain, Jianan Hui, Diego Gianolio, Assaf Vestin, Rui Ding, Prapti Patel, Stéphane De Botton, Hartmut Döhner, Jianxiang Wang

Blood (2025) 146 (Supplement 1): 3440.

https://doi.org/10.1182/blood-2025-3440

Published: 2025

Journal Articles

Revumenib for patients with relapsed or refractory (R/R) Nucleophosmin 1–Mutated (NPM1m) Acute Myeloid Leukemia (AML): Outcomes by prior treatment in the phase 2 AUGMENT-101 study

Blood (2025) 146 (Supplement 1): 3418.

https://doi.org/10.1182/blood-2025-3418

Published: 2025

Journal Articles

Diagnostic evaluation methods and prognostic impact of FLT3-ITD microclones in Acute Myeloid Leukemia (AML): A retrospective multicenter study on behalf of the EHA AML-specialized working group (SWG)

Blood (2025) 146 (Supplement 1): 217.

https://doi.org/10.1182/blood-2025-217

Published: 2025

Journal Articles

Phase 3 Study of ivosidenib (IVO) and azacitidine (AZA) with or without venetoclax in adult patients with newly diagnosed IDH1-mutated AML or MDS/AML ineligible for intensive chemotherapy (EVOLVE-1)

Hartmut Döhner, Gerwin A. Huls, Paresh Vyas

Blood (2025) 146 (Supplement 1): 5192.

https://doi.org/10.1182/blood-2025-5192

Published: 2025

Journal Articles

Real-world experience with IDH inhibitors in Acute Myeloid Leukemia: A german multicenter analysis with a focus on differentiation syndrome

Krischan Braitsch, Karin Huber, Andrew Berdel, Lydia Kretschmer, Adrian Gottschlich, Tim Lohmann, Kathrin Rieger, Karsten Spiekermann, Thomas Schroeder, Silke Kapp-Schwoerer, Mareike Verbeek, Florian Bassermann, Hartmut Döhner, Tim Sauer, Christoph Röllig, Jan-Henrik Mikesch, Franziska Westendorf, Lars Fransecky, Katharina S. Götze

Blood (2025) 146 (Supplement 1): 2846.

https://doi.org/10.1182/blood-2025-2846

Published: 2025

Journal Articles

Validation of measurable residual disease as a surrogate endpoint in acute myeloid leukemia: A HARMONY Alliance study of European randomized trials

Blood (2025) 146 (Supplement 1): 343.

https://doi.org/10.1182/blood-2025-343

Published: 2025

Journal Articles

Phase 1b study of bleximenib in combination with venetoclax in Acute Myeloid Leukemia with KMT2A or NPM1 alterations

Jenny O'Nions, Andrew Wei, Jordi Esteve, Ibrahim Aldoss, Ana Alfonso-Pierola, Alicia Allred, Juan Manuel Alonso-Dominguez, Laura Barreyro, Pierre Bories, Nikki Daskalakis, Matteo Della Porta, Hartmut Döhner, Amber D'Souza, James Dugan, Amir Fathi, Pasquale Fedele, Lucille Ferrante, Rachel Kobos, Ana Garrido, Sara Garrido Paniagua, Christina Drenberg Guttke, Emmanuel Gyan, Brett Hiebert, Elias Jabbour, Danielle Trancucci, Naa Sackey, Madlen Jentzsch, Hagop Kantarjian, Marina Konopleva, Jan Krönke, Marie Luise Hütter-Krönke, Christina Loefgren, Oliver Lomas, Valentina Mancini, Daniel Morillo, Kathryn Packman, Cristina Papayannidis, Christian Recher, Christoph Röllig, Olga Salamero, Prathap Nagaraja Shastri, Tim Sauer, Dr. Emma Searle, Natalia Tovar, Nicolas Vallet, Lachlin Vaughan, Paresh Vyas, Uwe Platzbecker, Sylvain Garciaz

Blood (2025) 146 (Supplement 1): 5200.

https://doi.org/10.1182/blood-2025-5200

Published: 2025

Journal Articles

Bleximenib in combination with intensive chemotherapy: A phase 1b study in newly diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 alterations

Hartmut Döhner, Andre Schuh, Christian Recher, Jenny O'Nions, Ibrahim Aldoss, Ana Alfonso-Pierola, Alicia Allred, Juan Manuel Alonso-Dominguez, Laura Barreyro, Pierre Bories, Nikki Daskalakis, Matteo Della Porta, Amber D'Souza, James Dugan, Jordi Esteve, Amir Fathi, Lucille Ferrante, Stan Gaj, Sylvain Garciaz, Ana Garrido, Olga Salamero, Christina Drenberg Guttke, Emmanuel Gyan, Brett Hiebert, Elias Jabbour, Madlen Jentzsch, Hagop Kantarjian, Marina Konopleva, Jan Krönke, Marie Luise Hütter-Krönke, Christina Loefgren, Oliver Lomas, Valentina Mancini, Ioannis Mantzaris, Daniel Morillo, Kathryn Packman, Cristina Papayannidis, Ulrike Philippar, Uwe Platzbecker, Sara Garrido Paniagua, Naa Sackey, Tim Sauer, Dr. Emma Searle, Prathap Nagaraja Shastri, Danielle Trancucci, Natalia Tovar, Nicolas Vallet, Lachlin Vaughan, Paresh Vyas, Andrew Wei, Christoph Röllig

Blood (2025) 146 (Supplement 1): 5199.

https://doi.org/10.1182/blood-2025-5199

Published: 2025

Journal Articles

Independent, international validation of the unsupervised harmony classification of Acute Myeloid Leukemia

Blood (2025) 146 (Supplement 1): 451.

https://doi.org/10.1182/blood-2025-451

Published: 2025

Journal Articles

Bleximenib or placebo in combination with standard induction and consolidation therapy followed by maintenance for the treatment of patients with newly diagnosed KMT2A-rearranged or NPM1-mutant Acute Myeloid Leukemia eligible for intensive chemotherapy: A double-blind Phase 3 study (HOVON 181 AML / AMLSG 37-25)

Blood (2025) 146 (Supplement 1): 1654.

https://doi.org/10.1182/blood-2025-1654

Published: 2025

Journal Articles

Updated response and safety analyses from a Phase 1 study of ivosidenib combined with intensive chemotherapy in patients with newly diagnosed (ND) Acute Myeloid Leukemia with isocitrate dehydrogenase (IDH)1 mutation

Blood (2025) 146 (Supplement 1): 992.

https://doi.org/10.1182/blood-2025-992

Published: 2025

Journal Articles

The addition of a tyrosine kinase inhibitor to intensive chemotherapy significantly improves outcome in de novo BCR::ABL1+ acute myeloid leukemia treated with intensive chemotherapy

Sarah Bertoli, Niklas Landberg, Emilie Bérard, Camille Gondran, Laetitia Largeaud, Véronique De Mas, Pierre-Yves Dumas, Arnaud Pigneux, Audrey Bidet, Sylvain Garciaz, Ludovic Gabellier, Gabrielle Roth-Guepin, Corentin Orvain, Pierre Peterlin, Rudy Birsen, Magda Alexis, Martin Carre, Emmanuelle Tavernier, Marion Boissard Simonet, Chantal Himberlin, Marc Maynadié, Kamel Laribi, Cécile Moluçon-Chabrot, Amine Belhabri, Samy Chraibi, Quentin Cabrera, Delphine Lebon, Emmanuel Raffoux, Thomas Cluzeau, Jean-Baptiste Micol, Mathieu Leclerc, Céline Berthon, Herve Dombret, Gunnar Juliusson, Anna Robelius, Sören Lehmann, Martin Jädersten, Lovisa Wennström, Pau Montesinos, Carmen Botella, Juan Miguel Bergua Burgues, Raimundo Garcia, Josefina Serrano, Mariluz Amigo, Patricia Garcia Ramirez, Claudia Sossa, Juan Manuel Alonso-Dominguez, Hartmut Döhner, Konstanze Döhner, Daniela Späth, Michael Kühn, Claudia Lengerke, Hans-Jörg Tischler, Christoph Röllig, Leo Ruhnke, Christian Thiede, Andreas Burchert, Hubert Serve, Carsten Mueller-Tidow, Claudia Baldus, Jurjen Versluis, Peter Valk, Daniel Kristensen, Anne Stidsholt Roug, Jiri Mayer, Mika Kontro, Pia Ettala, Vladimir Lazarevic, Christian Recher

Blood (2025) 146 (Supplement 1): 991.

https://doi.org/10.1182/blood-2025-991

Published: 2025

Journal Articles

A noncoding mutation in the NOTCH1 gene initiates oncogenic NOTCH signaling via wild-type NICD stabilization in CLL

Min Guo, Tugba Memis, Alena Sophie Ehrmann, Anselm Pittrof, Bernd Baumann, Francesca Ferrante, Eugen Tausch, Kirsten Fischer, Hartmut Döhner, Tilman Borggrefe, Stephan Stilgenbauer, Ulrich Pannicke, Klaus Schwarz, Daniel Mertens, Franz Oswald

Blood (2025) 146 (16): 1936–1949.

https://doi.org/10.1182/blood.2025028529

Published: 2025

Includes: Supplemental data

Journal Articles

Menin inhibition with revumenib for NPM1 -mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study

Blood (2025) 146 (9): 1065–1077.

https://doi.org/10.1182/blood.2025028357

Published: 2025

Includes: Supplemental data

Journal Articles

The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy

Blood (2025) 146 (5): 601–611.

https://doi.org/10.1182/blood.2024027506

Published: 2025

Includes: Supplemental data

Journal Articles

Acute promyelocytic leukemia: long-term outcomes from the HARMONY project

Blood (2025) 145 (2): 234–243.

https://doi.org/10.1182/blood.2024026186

Published: 2025

Includes: Supplemental data

Journal Articles

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

Blood (2024) 144 (21): 2169–2173.

https://doi.org/10.1182/blood.2024025409

Published: 2024

Journal Articles

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine

Hartmut Döhner, Keith W. Pratz, Courtney D. DiNardo, Andrew H. Wei, Brian A. Jonas, Vinod A. Pullarkat, Michael J. Thirman, Christian Récher, Andre C. Schuh, Sunil Babu, Xiaotong Li, Grace Ku, Zihuan Liu, Yan Sun, Jalaja Potluri, Monique Dail, Brenda Chyla, Daniel A. Pollyea

Blood (2024) 144 (21): 2211–2222.

https://doi.org/10.1182/blood.2024024944

Published: 2024

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Proteogenomic analysis of NPM1-mutated AML reveals clinical heterogeneity related to differentiation states and mitochondrial metabolism

ALIDHE: An ongoing open-label phase 3b study investigating ivosidenib with azacitidine in clinical practice in adult patients with newly diagnosed mutant isocitrate dehydrogenase 1 (mIDH1) Acute Myeloid Leukemia (AML) ineligible for intensive induction chemotherapy (IC)

CYP3A4 inhibitors (CYP3A4i) and myelosuppression in patients (Pts) with newly diagnosed mutant isocitrate dehydrogenase 1 (mIDH1) Acute Myeloid Leukemia (AML) in the phase 3 AGILE study

Revumenib for patients with relapsed or refractory (R/R) Nucleophosmin 1–Mutated (NPM1m) Acute Myeloid Leukemia (AML): Outcomes by prior treatment in the phase 2 AUGMENT-101 study

Diagnostic evaluation methods and prognostic impact of FLT3-ITD microclones in Acute Myeloid Leukemia (AML): A retrospective multicenter study on behalf of the EHA AML-specialized working group (SWG)

Phase 3 Study of ivosidenib (IVO) and azacitidine (AZA) with or without venetoclax in adult patients with newly diagnosed IDH1-mutated AML or MDS/AML ineligible for intensive chemotherapy (EVOLVE-1)

Real-world experience with IDH inhibitors in Acute Myeloid Leukemia: A german multicenter analysis with a focus on differentiation syndrome

Validation of measurable residual disease as a surrogate endpoint in acute myeloid leukemia: A HARMONY Alliance study of European randomized trials

Phase 1b study of bleximenib in combination with venetoclax in Acute Myeloid Leukemia with KMT2A or NPM1 alterations

Bleximenib in combination with intensive chemotherapy: A phase 1b study in newly diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 alterations

Independent, international validation of the unsupervised harmony classification of Acute Myeloid Leukemia

Updated response and safety analyses from a Phase 1 study of ivosidenib combined with intensive chemotherapy in patients with newly diagnosed (ND) Acute Myeloid Leukemia with isocitrate dehydrogenase (IDH)1 mutation

The addition of a tyrosine kinase inhibitor to intensive chemotherapy significantly improves outcome in de novo BCR::ABL1+ acute myeloid leukemia treated with intensive chemotherapy

A noncoding mutation in the NOTCH1 gene initiates oncogenic NOTCH signaling via wild-type NICD stabilization in CLL

Menin inhibition with revumenib for NPM1 -mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study

The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy

Acute promyelocytic leukemia: long-term outcomes from the HARMONY project

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only